Clinical trials: Gene Expression Profiling
Metastatic Breast Cancer
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
This study will use proteomic and genomic profiling to analyze tumor tissue to see if treatment selected by this analysis will benefit patients.
- Trial name
- SO2 (NCT01919749)
- Testing
- treated recommended
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Translational Drug Development
Sepsis, Emergent Infections, Treatment
Droplet Digital PCR Combines With Transcriptome Analysis in Early Warning of Sepsis in the Emergency Department
Rapid identification of pathogens and early warning of host response are key to improve the prognosis of sepsis. Establishing a comprehensive identification system based on pathogen identification and host immune status is an…
- Trial name
- NCT06028178
- Testing
- Droplet digital PCR
- Volunteers
- 360 people
- Sponsor
- Shanghai East Hospital
Spontaneous Miscarriage
Technical Feasibility of the cfDNA Test for Non-invasive Cytogenetic Analysis of Early Miscarriages Versus the Gold Standard Microarray
Among the 15% of couples who experience a spontaneous early miscarriage (SEM) during their pregnancy, approximately 2 to 5% will suffer from recurrent SEM.
- Trial name
- NICAEA (NCT05900076)
- Testing
- Curettage for the evacuation of the product of conception
- Where
- 2 sites in France
- Volunteers
- 78 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Cancer, Colon Cancer
Molecular Profiling of Colorectal Cancer
In this translational research study, Formalin-Fixed-Paraffin-Embedded (FFPE) tumor tissue blocks from patients with early-stage (II-III) colorectal cancer will be assessed for a comprehensive cancer gene panel from NIPD Genetics…
- Conditions
- Colorectal Cancer, Colon Cancer, Colon Adenocarcinoma
- Trial name
- NCT04863768
- Testing
- Gene panel
- Where
- Greece
- Volunteers
- 300 people
- Sponsor
- Hellenic Cooperative Oncology Group
Squamous Cell Carcinoma of the Head and Neck
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
The purpose of this study was to identify which cancer-related genes are turned on or turned off in order to determine how well a patient will respond to the study drug, panitumumab.
- Trial name
- TOP0901 (NCT01305772)
- Testing
- Panitumumab, Surgery, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neal Ready
Advanced Breast Cancer, Advanced Breast Carcinoma
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
This trial studies a type of advanced breast cancer defined as hormone receptor HR-positive/HER2-negative and classified as non-luminal by gene expression profiling (PAM50).
- Conditions
- Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
- Trial name
- PONTIAC (NCT06486883)
- Testing
- Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET
- Where
- 79 sites in Austria, Belgium and 8 more
- Volunteers
- 200 people
- Sponsor
- MedSIR
Allergy Pollen
Microassay and Allergy Skin Prick Test Correlation Study
The purpose of this study is to evaluate the potential correlation of the results of allergen-specific skin prick tests (SPT) to that of allergen-specific microarray determination (microassay test).
- Trial name
- NCT03514303
- Testing
- Spiriplex Allergenex Microassay
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Kidney Cancer, Biomarkers
Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas
Renal cell carcinoma accounts for 2-3% of all cancers in western countries. Brazilian kidney cancer data show an incidence of 6,270 new cases for 2018.
- Conditions
- Kidney Cancer, Biomarkers, Gene Expression
- Trial name
- NCT04415697
- Testing
- Gene expression test using nanostring technology.
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Barretos Cancer Hospital
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Cancer
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
This pilot study will help us to determine the success of using a special technique called microarray technology to examine cancer genes in order to predict how individual women will respond to one of two therapies, liposomal…
- Trial name
- NCT00720096
- Testing
- Liposomal Doxorubicin, Topotecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Mantle Cell Lymphoma
Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
Retrospective observational study with a prospective biological evaluation of an historical cohort of first relapsed-refractory patients with mantle cell lymphoma who were relapsed or refractory to rituximab and chemotherapy…
- Trial name
- NCT04882475
- Where
- 16 sites in Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diabetes, Diabetes Mellitus
Biolinq External Interferent Protocol
The primary objective of the study is to evaluate the interference effect of acetaminophen (APAP) on the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System during a single in-clinic day on Day 3 of the sensor…
- Trial name
- NCT06560177
- Testing
- The Biolinq MicroArray Intradermal Continuous Glucose Biowearable System
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Biolinq Inc.
In Vitro Fertilization
EXpression PRofile Endometrium Samples Study
This is a Phase IV, pilot, open-label, national, multi-centric study planned to determine the gene expression profiles and histologic changes of the endometrial tissue before and after stimulation with Gonal-f®.
- Trial name
- EXPRESS (NCT01210144)
- Testing
- Gonal -f® [r-hFSH], Ovitrelle® [r-hCG alfa], Gonadotropin-releasing hormone (GnRH) Agonist
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
This randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT01293032
- Testing
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Virginia Commonwealth University
Central Nervous System Lymphoma
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967200
- Testing
- laboratory biomarker analysis, pharmacogenomic studies
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Montpellier
Acute Myeloid Leukemia
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
This is a multicenter, prospective, translational study, to evaluate the immunogenic profile of AML cases according to immune checkpoint molecule expression.
- Trial name
- Immune-AML (NCT03789981)
- Testing
- Immunogenic profile
- Where
- 14 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Colon Cancer
A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile
This study is a parallel translational study of a Randomized Phase III trial Investigating the Role of Oxaliplatin duration (6 Cycles Versus 12 Cycles) in modified FOLFOX-6 Regimen as Adjuvant Therapy for Patients with Stage…
- Trial name
- NCT01472601
- Where
- South Korea
- Volunteers
- 2,660 people
- Sponsor
- Samsung Medical Center
Heart Transplantation, Graft Rejection
ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study
The goal of this observational study is to evaluate whether molecular analysis of donor heart biopsies taken at the time of organ removal ("Time Zero") can help predict the future function and rejection risk of the transplanted…
- Conditions
- Heart Transplantation, Graft Rejection, Myocardial Injury, Organ Preservation
- Trial name
- ZeroHeart (NCT06982404)
- Testing
- Time Zero Donor Heart Biopsy for Molecular Analysis
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Neurofibromatosis Type 1
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
Neurofibromatosis type 1 (NF1) is a frequent autosomal dominant disorder, caused by heterozygous mutations of the NF1 tumor suppressor gene (chr.17q11.2).
- Trial name
- NCT01218152
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Mental Retardation, Syndromic Obesity
Microarray Analysis in Syndromic Obesity
Comparative genomic hybridization (CGH) array technology has been used in numerous studies on mental retardation, and few chromosomal abnormalities have been identified in patients.
- Trial name
- REMOB (NCT01043198)
- Testing
- Clinical examination and blood sampling for biological and genetic analysis
- Where
- 6 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Bordeaux